Clinical Pearl

Direct acting antivirals (telaprevir, boceprevir) are associated with more side effects than the old standard of therapy for HCV with PegInterferon and Ribavirin.  The new, triple regimens are associated with drug discontinuation in 8% of cases, from adverse events such as: fatigue, pruritus, nausea, headache, anemia, rash, influenza-like illness, insomnia, pyrexia and diarrhea.

This entry was posted in Clinical Pearl. Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s